Antisense Therapeutics (ASX:ANP) receives first approval for phase two DMD clinical trial

Antisense Therapeutics (ASX:ANP) has received approval to conduct its phase two trial in non-ambulant boys with DMD in Turkey.

Related Keywords

Australia ,Bulgaria ,United Kingdom ,Turkey ,Turkish ,Thomas Voit ,Haluk Topalo ,Device Agency ,Antisense Therapeutics ,Turkish Medicines ,Medical Device Agency ,Principal Investigator ,Professor Thomas Voit ,Professor Haluk Topalo ,National Coordinating ,